Omentum preservation versus complete omentectomy in gastrectomy for gastric cancer - OMEGA trial

Academisch Medisch Centrum0 个研究点目标入组 554 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•- Primary resectable gastric adenocarcinoma, clinical stage T1-4aN0-3M0
•- ASA 1-3 (able to undergo surgery)
•- Scheduled for open or minimally invasive (sub)total gastrectomy with modified
•D2-lymphadenectomy, with or without perioperative chemotherapy
•- Age above 18 year
•- Able to complete questionnaires in Dutch, English or Italian
•- Written informed consent
•- Esophageal invasion < 2 cm defined from the upper margin of the gastric rugae
•as determined by endoscopy

•- Gastric cancer clinically staged as T1N0
•- Locally advanced gastric cancer requiring multi-visceral resection
•- Pregnancy
•- Previous malignancy (excluding non-melanoma skin cancer, pancreatic
•neuroendocrine tumor (pNET) <2cm, and gastrointestinal stromal tumor (GIST)
•<2cm), unless no evidence of disease and diagnosed more than three years before
•diagnosis of gastric cancer, or with a life expectancy of more than five years
•from date of inclusion
•- Serious concomitant systemic disorders that would compromise the safety of
•the patient or his/her ability to complete the study, at the discretion of the
•investigator
•- Previous gastric or omental surgery, with the exclusion of a gastric
•perforation
•- Indication for thoracotomy/thoracoscopy

发起方